Table 3.

Univariate Cox proportional hazards model for time-to progression (TTP), and overall survival (OS)

	Time-to progression			OS
	HR	95 % CI	P	HR	95 % CI	P
BRCA status
BRCA1/2 positive vs. negative	1.34	0.90–2.02	0.15	1.48	0.89–2.44	0.13
BRCA1 positive vs. negative	1.43	0.89–2.28	0.30*	2.2	1.28–3.78	0.004
BRCA2 positive vs. negative	1.19	0.60–2.35		0.52	0.16–1.67	0.27
Age
>38.6 vs. ≤38.6	0.92	0.66–1.28	0.62	0.92	0.61–1.40	0.72
Tumor size of primary tumor
T4 vs. T1	1.73	1.01–2.97	0.20*	1.97	0.93–4.14	0.08*
T3 vs. T1	1.56	0.83–2.91		2.46	1.19–5.09
T2 vs. T1	1.27	0.83–1.93		1.65	0.93–2.92
Nodal status
N3 vs. N0	1.69	1.00–2.86	0.03*	2.15	1.16–3.97	0.01*
N2 vs. N0	0.78	0.44–1.38		1.03	0.52–2.05
N1 vs. N0	0.80	0.52–1.22		0.76	0.43–1.33
Clinical stagea
M0 vs. M1	0.45	0.28–0.73	0.001	0.47	0.25–0.90	0.02
Nuclear grade
3 vs. 1/2	1.93	1.19–3.11	0.006	2.38	1.38–4.10	0.001
ER-status
Positive vs. negative	0.83	0.59–1.17	0.30	0.54	0.35–0.83	0.004
PR-status
Positive vs. negative	0.73	0.52–1.04	0.08	0.46	0.29–0.74	0.001
HER2-status
Positive vs. negative	0.68	0.44–1.06	0.09	0.50	0.28–0.91	0.02
Triple-negative
Yes vs. no	1.78	1.18–2.68	0.005	2.60	1.62–4.14	\0.0001
FH of breast cancer
Positive vs. negative	0.61	0.42–0.90	0.01	0.62	0.39–1.00	0.05
FH of ovarian cancer
Positive vs. negative	0.82	0.50–1.33	0.42	1.19	0.68–2.09	0.53
Site of first metastasis
Visceral vs. bone-only	2.16	1.40–3.33	<0.0001*	2.04	1.15–3.61	0.002*
Mixed vs. bone-only	2.89	1.83–4.57		3.02	1.70–5.37
Number of metastatic sites
3 vs. 1–2	2.08	1.41–3.06	0.0002	2.75	1.77–4.27	<0.0001
Herceptin use
Yes vs. no	0.95	0.63–1.42	0.81	0.60	0.33–1.06	0.08
Lapatinib use
Yes vs. no	1.26	0.80–1.99	0.31	0.90	0.50–1.63	0.74
Bisphosphonates use
Yes vs. no	0.79	0.55–1.12	0.19	0.61	0.38–0.97	0.04

^*P value for overall effect

^aClinical stage at initial diagnosis